Company Of The Day: Merck
What?
The U.S. FDA approved a new version of Merck’s (NYSE:MRK) pneumococcal vaccine that prevents invasive disease caused by 15 strains of bacteria called Streptococcus pneumoniae.
So What?
- Will Higher Keytruda Sales Drive Merck’s Q1
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- At $100 Does Merck Stock Have Room For Growth?
- Should You Pick Merck Stock Over Coca-Cola?
- Should You Buy Merck Stock After An Upbeat Q2?
- How Has Merck Stock Performed During The 2022-23 Inflation Shock?
Pneumococcal vaccines are lucrative and were the single largest vaccine market by revenue prior to Covid-19. Pfizer’s blockbuster Prevnar 13, which generates over $5.8 billion in annual sales is the market leader in the space.
While Merck’s new shot protects against a few more strains compared to Prevnar 13, the successor to Prevnar, which was approved in June, covers a total of 20 strains. That said, Merck notes that its shot provides a stronger immune response against a strain called serotype 3, which is the leading cause of invasive pneumococcal diseases in adults in the United States.
See Our Complete Analysis For Merck
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams